Sign up to save your podcasts
Or
Share Why This Quarter Could Be Vital for Cybin's FDA Milestones! | TDR Exclusive
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why This Quarter Could Be Vital for Cybin's FDA Milestones! | TDR Exclusive
Welcome to our latest TDR exclusive! In this episode with Doug Drysdale, CEO of Cybin we get into their groundbreaking developments in mental healthcare, including FDA clearance for a Phase 2a study of CYB004 in Generalized Anxiety Disorder, the positive impact of CYB003 on MADRS scores, and the future of psychedelic therapies in the industry. Stay tuned for exclusive insights into the evolving landscape of mental health treatments and Cybin's mission to revolutionize the field.
Guest: Doug Drysdale, CEO of Cybin
🔥 Join us for an in-depth interview with Cybin Inc., where we explore groundbreaking developments in mental healthcare and psychedelic treatments!
🧠 Learn about Cybin's FDA clearance for the Phase 2a study of CYB004 in Generalized Anxiety Disorder (GAD) and its mission to revolutionize mental healthcare.
💊 Discover the positive impact of CYB003 on MADRS scores, its significance in the market, and safety considerations.
🌌 Gain insights into Phase 1 studies of proprietary deuterated DMT molecules CYB004 and SPL028, and their role in safer and more effective mental health treatments.
💡 Discuss industry inflection points, potential legislative changes, and the impact of FDA decisions on psychedelic therapies.
📅 Get an exclusive timeline for CYB004's Phase 2a study in GAD and other near-term catalysts in 2024!
Stay tuned for insights into the future of mental healthcare and Cybin Inc.'s exciting developments! Subscribe now! 🌟 #MentalHealth #PsychedelicTherapies #CybinInc #FDAApproval #Innovation
View all episodes
By Dales Media Group
5
77 ratings
Welcome to our latest TDR exclusive! In this episode with Doug Drysdale, CEO of Cybin we get into their groundbreaking developments in mental healthcare, including FDA clearance for a Phase 2a study of CYB004 in Generalized Anxiety Disorder, the positive impact of CYB003 on MADRS scores, and the future of psychedelic therapies in the industry. Stay tuned for exclusive insights into the evolving landscape of mental health treatments and Cybin's mission to revolutionize the field.
Guest: Doug Drysdale, CEO of Cybin
🔥 Join us for an in-depth interview with Cybin Inc., where we explore groundbreaking developments in mental healthcare and psychedelic treatments!
🧠 Learn about Cybin's FDA clearance for the Phase 2a study of CYB004 in Generalized Anxiety Disorder (GAD) and its mission to revolutionize mental healthcare.
💊 Discover the positive impact of CYB003 on MADRS scores, its significance in the market, and safety considerations.
🌌 Gain insights into Phase 1 studies of proprietary deuterated DMT molecules CYB004 and SPL028, and their role in safer and more effective mental health treatments.
💡 Discuss industry inflection points, potential legislative changes, and the impact of FDA decisions on psychedelic therapies.
📅 Get an exclusive timeline for CYB004's Phase 2a study in GAD and other near-term catalysts in 2024!
Stay tuned for insights into the future of mental healthcare and Cybin Inc.'s exciting developments! Subscribe now! 🌟 #MentalHealth #PsychedelicTherapies #CybinInc #FDAApproval #Innovation
More shows like The Dales Report | Trade to Black
View all
Blunt Business
40 Listeners
Modern Wisdom
3,765 Listeners
Mining Stock Daily
95 Listeners
The Pomp Podcast
1,835 Listeners
The Cannabis Investing Podcast
204 Listeners
Cannabis Investing Network
70 Listeners
The Prof G Pod with Scott Galloway
5,434 Listeners
The Memo by Howard Marks
401 Listeners
The Dime
104 Listeners
Huberman Lab
28,589 Listeners
Honestly with Bari Weiss
8,598 Listeners
On The Tape with Danny Moses
155 Listeners
High Spirits: The Cannabis Business Podcast
6 Listeners
Higher Exchanges
11 Listeners
Prof G Markets
1,164 Listeners